Managing cardiovascular risk inpatients with metabolic syndrome

2002, Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol inadults (Adult Treatment Panel 111). Final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 Grobbee, 2005 Ford, 2002, Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey, JAMA, 287, 356, 10.1001/jama.287.3.356 Ford, 2004, Increasing prevalence of the metabolic syndrome among U.S. adults, Diabetes Care, 27, 2444, 10.2337/diacare.27.10.2444 Duncan, 2004, Prevalence and trends of a metabolic syndrome phenotype among U.S. adolescents, 1999–2000, Diabetes Care, 27, 2438, 10.2337/diacare.27.10.2438 Grundy, 2004, American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition, Circulation., 109, 433, 10.1161/01.CIR.0000111245.75752.C6 Tamsma, 2005, The metabolic syndrome: A vascular perspective, Eur J Intern Med., 16, 314, 10.1016/j.ejim.2005.01.011 Lakka, 2002, The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men, JAMA, 288, 2709, 10.1001/jama.288.21.2709 Levantesi, 2005, Metabolic syndrome and risk of cardiovascular events after myocardial infarction, J Am Coll Cardiol, 46, 277, 10.1016/j.jacc.2005.03.062 Gorter, 2004, Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominalaortic aneurysm, Atherosclerosis, 173, 363, 10.1016/j.atherosclerosis.2003.12.033 Assmann, 2004, Cardiovascular risk assessment in metabolic syndrome: View from PROCAM, Endocrinol Metab Clin North Am., 33, 377, 10.1016/j.ecl.2004.03.017 Rosenson, 2005, Assessing risk across the spectrum of patients with the metabolic syndrome, Am J Cardiol., 96, 8E, 10.1016/j.amjcard.2005.05.007 Otvos, 2003, LDL particles, but not LDL cholesterol, are highly elevated in the metabolic syndrome. Results from the Framingham Offspring Study Wilson, 2004, Estimating cardiovascular disease risk and the metabolic syndrome: A Framingham view, Endocrinol Metab Clin North Am., 33, 467, 10.1016/j.ecl.2004.03.012 Wilson, 1999, Clustering of metabolic factors and coronary heart disease, Arch Intern Med., 159, 1104, 10.1001/archinte.159.10.1104 Koenig, 2004, C-reactive protein modulates risk prediction based on the Framingham Score: Implications for future risk assessment: Results froma large cohort study in southern Germany, Circulation, 109, 1349, 10.1161/01.CIR.0000120707.98922.E3 Rajaram, 2004, Role of surrogate markers in assessing patients with diabetes mellitus and the metabolic syndrome and in evaluating lipid-lowering therapy, Am J Cardiol., 93, 32C, 10.1016/j.amjcard.2004.02.004 Vega, 2003, Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome, Am J Cardiol., 91, 956, 10.1016/S0002-9149(03)00111-5 Purnell, 2003, Weight effect of current and experimental drugs for diabetes mellitus: From promotion to alleviation of obesity, Treat Endocrinol, 2, 33, 10.2165/00024677-200302010-00004 Di Marzo, 2005, Endocannabinoid control of food intake and energy balance, Nat Neurosci., 8, 585, 10.1038/nn1457 Van Gaal, 2005, Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-yearexperience from the RIO-Europe study, Lancet, 365, 1389, 10.1016/S0140-6736(05)66374-X